经皮肾肿瘤消融:长期结果

J.L. del Cura Rodríguez , R. Zabala-Landa , I. Korta-Gomez
{"title":"经皮肾肿瘤消融:长期结果","authors":"J.L. del Cura Rodríguez ,&nbsp;R. Zabala-Landa ,&nbsp;I. Korta-Gomez","doi":"10.1016/j.rxeng.2021.12.003","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>To evaluate the long-term outcomes of renal tumor ablation, analyzing efficacy, long-term survival, and factors associated with complications and therapeutic success.</p></div><div><h3>Material and methods</h3><p>We retrospectively reviewed 305 ablations (generally done with expandable electrodes) of 273 renal tumors between May 2005 and April 2019. We analyzed survival, primary and secondary efficacy, and complications according to various patient factors and tumor characteristics.</p></div><div><h3>Results</h3><p><span>Mean blood creatinine was 1.14 mg/dL before treatment and 1.30 mg/dL after treatment (</span><em>p</em> &lt; 0.0001). Complications were observed in 13.25% of the ablations, including major complications in in 4.97%. Complications were associated with age (<em>p</em> = 0.013) and tumor diameter (<em>p</em> &lt; 0.0001). Primary efficacy was 96.28%. Incomplete ablation was more common in lesions measuring &gt; 4 cm in diameter (<em>p</em> = 0.002). Secondary efficacy was 95.28%. The only factor associated with the risk of recurrence was the size of the tumor (<em>p</em><span><span> = 0.02). Overall survival was 95.26% at 1 year, 77.01% at 5 years, and 51.78% at 10 years, with no differences between patients with malignant and benign lesions. Mortality was higher </span>in patients with creatinine &gt;1 (</span><em>p</em><span> = 0.05) or ASA &gt; 2 (</span><em>p</em> = 0.0001).</p></div><div><h3>Conclusions</h3><p>Percutaneous ablation is extremely efficacious for renal tumors; it improves the prognosis of renal carcinoma to the point where it does not differ from that of benign lesions. Complications are rare. Like survival, complications are associated with age and overall health status.</p></div>","PeriodicalId":94185,"journal":{"name":"Radiologia","volume":"65 6","pages":"Pages 492-501"},"PeriodicalIF":0.0000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Percutaneous ablation of renal tumors: Long-term outcomes\",\"authors\":\"J.L. del Cura Rodríguez ,&nbsp;R. Zabala-Landa ,&nbsp;I. Korta-Gomez\",\"doi\":\"10.1016/j.rxeng.2021.12.003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><p>To evaluate the long-term outcomes of renal tumor ablation, analyzing efficacy, long-term survival, and factors associated with complications and therapeutic success.</p></div><div><h3>Material and methods</h3><p>We retrospectively reviewed 305 ablations (generally done with expandable electrodes) of 273 renal tumors between May 2005 and April 2019. We analyzed survival, primary and secondary efficacy, and complications according to various patient factors and tumor characteristics.</p></div><div><h3>Results</h3><p><span>Mean blood creatinine was 1.14 mg/dL before treatment and 1.30 mg/dL after treatment (</span><em>p</em> &lt; 0.0001). Complications were observed in 13.25% of the ablations, including major complications in in 4.97%. Complications were associated with age (<em>p</em> = 0.013) and tumor diameter (<em>p</em> &lt; 0.0001). Primary efficacy was 96.28%. Incomplete ablation was more common in lesions measuring &gt; 4 cm in diameter (<em>p</em> = 0.002). Secondary efficacy was 95.28%. The only factor associated with the risk of recurrence was the size of the tumor (<em>p</em><span><span> = 0.02). Overall survival was 95.26% at 1 year, 77.01% at 5 years, and 51.78% at 10 years, with no differences between patients with malignant and benign lesions. Mortality was higher </span>in patients with creatinine &gt;1 (</span><em>p</em><span> = 0.05) or ASA &gt; 2 (</span><em>p</em> = 0.0001).</p></div><div><h3>Conclusions</h3><p>Percutaneous ablation is extremely efficacious for renal tumors; it improves the prognosis of renal carcinoma to the point where it does not differ from that of benign lesions. Complications are rare. Like survival, complications are associated with age and overall health status.</p></div>\",\"PeriodicalId\":94185,\"journal\":{\"name\":\"Radiologia\",\"volume\":\"65 6\",\"pages\":\"Pages 492-501\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Radiologia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2173510723001428\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Radiologia","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2173510723001428","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

目的评价肾肿瘤消融治疗的远期效果,分析其疗效、长期生存、并发症及治疗成功的相关因素。材料和方法我们回顾性分析了2005年5月至2019年4月期间273例肾脏肿瘤的305例消融(通常使用可膨胀电极)。我们根据不同的患者因素和肿瘤特征分析患者的生存率、原发性和继发性疗效以及并发症。结果治疗前平均血肌酐为1.14 mg/dL,治疗后平均血肌酐为1.30 mg/dL (p <0.0001)。并发症发生率为13.25%,其中主要并发症发生率为4.97%。并发症与年龄(p = 0.013)和肿瘤直径(p <0.0001)。主要疗效为96.28%。不完全消融在测量>的病变中更为常见;直径4厘米(p = 0.002)。次要疗效为95.28%。与复发风险相关的唯一因素是肿瘤的大小(p = 0.02)。1年生存率为95.26%,5年生存率为77.01%,10年生存率为51.78%,良恶性病变患者无差异。肌酐≥1 (p = 0.05)或ASA≥1 (p = 0.05)的患者死亡率更高。(p = 0.0001)。结论经皮消融术治疗肾肿瘤疗效显著;它改善了肾癌的预后,使其与良性病变没有区别。并发症很少见。像生存一样,并发症与年龄和整体健康状况有关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Percutaneous ablation of renal tumors: Long-term outcomes

Objective

To evaluate the long-term outcomes of renal tumor ablation, analyzing efficacy, long-term survival, and factors associated with complications and therapeutic success.

Material and methods

We retrospectively reviewed 305 ablations (generally done with expandable electrodes) of 273 renal tumors between May 2005 and April 2019. We analyzed survival, primary and secondary efficacy, and complications according to various patient factors and tumor characteristics.

Results

Mean blood creatinine was 1.14 mg/dL before treatment and 1.30 mg/dL after treatment (p < 0.0001). Complications were observed in 13.25% of the ablations, including major complications in in 4.97%. Complications were associated with age (p = 0.013) and tumor diameter (p < 0.0001). Primary efficacy was 96.28%. Incomplete ablation was more common in lesions measuring > 4 cm in diameter (p = 0.002). Secondary efficacy was 95.28%. The only factor associated with the risk of recurrence was the size of the tumor (p = 0.02). Overall survival was 95.26% at 1 year, 77.01% at 5 years, and 51.78% at 10 years, with no differences between patients with malignant and benign lesions. Mortality was higher in patients with creatinine >1 (p = 0.05) or ASA > 2 (p = 0.0001).

Conclusions

Percutaneous ablation is extremely efficacious for renal tumors; it improves the prognosis of renal carcinoma to the point where it does not differ from that of benign lesions. Complications are rare. Like survival, complications are associated with age and overall health status.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信